Zacks Investment Research restated their hold rating on shares of ZIOPHARM Oncology (NASDAQ:ZIOP) in a research report sent to investors on Saturday morning.

According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “

A number of other research firms have also issued reports on ZIOP. ValuEngine lowered shares of ZIOPHARM Oncology from a hold rating to a sell rating in a report on Friday, September 15th. HC Wainwright reaffirmed a buy rating and set a $9.50 target price on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. BidaskClub raised shares of ZIOPHARM Oncology from a strong sell rating to a sell rating in a research report on Thursday, January 4th. Finally, Raymond James Financial reissued a hold rating on shares of ZIOPHARM Oncology in a research report on Monday, December 11th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. ZIOPHARM Oncology presently has a consensus rating of Hold and a consensus target price of $12.67.

ZIOPHARM Oncology (NASDAQ:ZIOP) traded up $0.10 during trading on Friday, hitting $4.36. 1,311,411 shares of the stock were exchanged, compared to its average volume of 1,734,040. ZIOPHARM Oncology has a fifty-two week low of $3.77 and a fifty-two week high of $7.88. The stock has a market capitalization of $618.96, a price-to-earnings ratio of -8.38 and a beta of 1.44.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. During the same period in the previous year, the company earned ($0.11) EPS. ZIOPHARM Oncology’s quarterly revenue was up .0% compared to the same quarter last year. sell-side analysts anticipate that ZIOPHARM Oncology will post -0.54 earnings per share for the current fiscal year.

In other news, CEO Laurence James Neil Cooper purchased 6,440 shares of the stock in a transaction dated Wednesday, November 8th. The shares were purchased at an average price of $4.68 per share, with a total value of $30,139.20. Following the transaction, the chief executive officer now owns 1,083,731 shares in the company, valued at approximately $5,071,861.08. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 10.40% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new position in shares of ZIOPHARM Oncology during the 3rd quarter valued at about $145,000. Belpointe Asset Management LLC acquired a new position in ZIOPHARM Oncology in the third quarter valued at about $746,000. Ladenburg Thalmann Financial Services Inc. lifted its position in ZIOPHARM Oncology by 127.5% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 25,896 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 14,513 shares during the last quarter. Chevy Chase Trust Holdings Inc. acquired a new position in ZIOPHARM Oncology in the third quarter valued at about $104,000. Finally, Schwab Charles Investment Management Inc. lifted its position in ZIOPHARM Oncology by 6.6% in the third quarter. Schwab Charles Investment Management Inc. now owns 618,589 shares of the biotechnology company’s stock valued at $3,799,000 after buying an additional 38,440 shares during the last quarter. 40.23% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This news story was published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2018/01/14/ziopharm-oncologys-ziop-hold-rating-reaffirmed-at-zacks-investment-research.html.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.